X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rheumatology (79) 79
humans (76) 76
systemic lupus erythematosus (57) 57
female (56) 56
bilag (55) 55
index medicus (54) 54
severity of illness index (48) 48
adult (47) 47
male (46) 46
middle aged (45) 45
lupus (40) 40
lupus erythematosus, systemic - drug therapy (36) 36
bilag index (33) 33
sle (24) 24
treatment outcome (23) 23
abridged index medicus (22) 22
adolescent (21) 21
disease activity (21) 21
disease-activity (21) 21
lupus erythematosus, systemic - diagnosis (20) 20
lupus erythematosus, systemic - physiopathology (20) 20
young adult (18) 18
lupus erythematosus, systemic - immunology (17) 17
classification (16) 16
aged (15) 15
erythematosus (15) 15
lupus erythematosus, systemic - complications (15) 15
sledai (15) 15
validation (15) 15
disease-activity index (13) 13
rituximab (13) 13
double-blind (12) 12
immunosuppressive agents - therapeutic use (12) 12
lupus nephritis (12) 12
nephritis (12) 12
follow-up studies (11) 11
quality of life (11) 11
autoantibodies (10) 10
child (10) 10
index (10) 10
lupus erythematosus, systemic - blood (10) 10
reliability (10) 10
therapy (10) 10
activity index (9) 9
antibodies, monoclonal, humanized - therapeutic use (9) 9
double-blind method (9) 9
quality-of-life (9) 9
united kingdom (9) 9
antibodies, monoclonal - therapeutic use (8) 8
arthritis (8) 8
autoimmune diseases (8) 8
b-lymphocyte stimulator (8) 8
bilag 2004 (8) 8
corticosteroids (8) 8
cross-sectional studies (8) 8
damage (8) 8
disease progression (8) 8
initial validation (8) 8
lupus erythematosus, systemic - pathology (8) 8
medical research (8) 8
prospective studies (8) 8
reproducibility of results (8) 8
revised criteria (8) 8
rheumatoid-arthritis (8) 8
skin and connective tissue diseases (8) 8
validity (8) 8
antibodies, antinuclear - blood (7) 7
association (7) 7
clinical-trials (7) 7
cohort studies (7) 7
dna - immunology (7) 7
dose-response relationship, drug (7) 7
drug therapy, combination (7) 7
epratuzumab (7) 7
flares (7) 7
immunology (7) 7
longitudinal studies (7) 7
medicine & public health (7) 7
mortality (7) 7
rheumatology damage index (7) 7
sledai-2k (7) 7
slicc/acr damage index (7) 7
analysis (6) 6
autoimmunity (6) 6
belimumab (6) 6
biomarkers - blood (6) 6
clinical trials (6) 6
immunologic factors - therapeutic use (6) 6
medicine, experimental (6) 6
monoclonal-antibody (6) 6
outcome measures (6) 6
prevalence (6) 6
retrospective studies (6) 6
sensitivity and specificity (6) 6
anti-dsdna (5) 5
antibodies, monoclonal, humanized (5) 5
b-lymphocytes - immunology (5) 5
biomarkers (5) 5
cd22 (5) 5
childhood (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 721 - 731
Journal Article
Pediatric Nephrology, ISSN 0931-041X, 2/2017, Volume 32, Issue 2, pp. 283 - 295
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 07/2014, Volume 14, Issue 7, pp. 1045 - 1047
Introduction: Systemic lupus erythematosus is an autoimmune multiorgan disease in which the lack of an appropriate therapy can lead to rapid organ failure and... 
quality of life | lupus | BILAG scores | epratuzumab
Journal Article
Journal Article
ANNALS OF THE RHEUMATIC DISEASES, ISSN 0003-4967, 10/2013, Volume 72, Issue 10, pp. 1639 - 1645
Objectives To evaluate and compare the clinical efficacy of three biomarkers for interferon (IFN) activity (measured directly and indirectly) and six... 
Systemic Lupus Erythematosus | ALPHA MONOCLONAL-ANTIBODY | I INTERFERON SYSTEM | Autoantibodies | Cytokines | INDUCIBLE GENE-EXPRESSION | MONONUCLEAR-CELLS | SERUM | RHEUMATOLOGY | ACTIVITY INDEX | PHASE-I | ASSOCIATION | Chemokines | BILAG INDEX | BLOOD | Lupus | Proteins | Studies | Medical research | Flow cytometry | Immunoglobulins | Mortality | Rheumatology | Biomarkers | Multivariate analysis | Age
Journal Article
Rheumatology, ISSN 1462-0324, 07/2005, Volume 44, Issue 7, pp. 902 - 906
Objective. To devise a more discriminating version of the British Isles Lupus Assessment Group (BILAG) disease activity index and to show that it is reliable.... 
Index | Disease activity | Systemic lupus erythematosus | Assessment | BILAG | AUTOANTIBODY PROFILES | assessment | systemic lupus erythematosus | FLARES | disease activity | index | RHEUMATOLOGY | Severity of Illness Index | Reproducibility of Results | Humans | Adult | Female | Male | Observer Variation | Lupus Erythematosus, Systemic - diagnosis
Journal Article
Nephron Clinical Practice, ISSN 1660-2110, 07/2005, Volume 100, Issue 3, pp. c92 - c100
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 02/2014, Volume 41, Issue 2, pp. 300 - 309
Journal Article
RHEUMATOLOGY, ISSN 1462-0324, 08/2019, Volume 58, Issue 8, pp. 1353 - 1360
Objective. To assess the responsiveness of clinical outcome measures in musculoskeletal SLE compared with US. Methods. A prospective pilot study was conducted... 
RHEUMATOID-ARTHRITIS | DERIVATION | BELIMUMAB | outcome measures | ultrasonography | systematic lupus erythematosus | INVOLVEMENT | VALIDATION | MONOCLONAL-ANTIBODY | tendons and ligaments | RHEUMATOLOGY | PHASE II/III | BILAG | SLEDAI | synovium | lupus arthritis | DISEASE-ACTIVITY INDEX | DOUBLE-BLIND | INFLAMMATORY ACTIVITY | Clinical Science
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2015, Volume 14, Issue 7, pp. 601 - 608
Abstract The assessment of disease activity in patients affected by Systemic Lupus Erythematosus (SLE) represents an important issue, as recommended by the... 
Allergy and Immunology | Systemic Lupus Erythematosus | SLEDAI | Disease activity | BILAG | ACTIVITY INDEX 2000 | SLE PATIENTS | VALIDATION | IMMUNOLOGY | DAMAGE | RESPONDER INDEX | CLINICAL-TRIALS | DOUBLE-BLIND | TO-TARGET | QUALITY-OF-LIFE | MONOCENTRIC COHORT | Lupus | Systemic lupus erythematosus | Diagnosis | Analysis
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 11/2017, Volume 76, Issue 11, pp. 1837 - 1844
ObjectivesSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with diffuse immune cell dysfunction. CD40–CD40 ligand (CD40L)... 
pharmacokinetics | systemic lupus erythematosus | autoantibodies | autoimmune disease | BILAG 2004 | UPDATED VERSION | CD40 LIGAND | MONOCLONAL-ANTIBODY | COSTIMULATION | COMPLICATIONS | RHEUMATOLOGY | ACTIVITY INDEX | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Immunologic Factors - administration & dosage | Male | Treatment Outcome | Lupus Erythematosus, Systemic - blood | Transcriptome - drug effects | Polyethylene Glycols - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Administration, Intravenous | Immunoglobulin Fab Fragments - administration & dosage | CD40 Ligand - drug effects | Adolescent | Lupus Erythematosus, Systemic - drug therapy | Adult | Female | Aged | RNA - blood | Treatment outcome | Usage | Care and treatment | Systemic lupus erythematosus | Polyethylene glycol | Analysis | Intravenous administration | CD40 antigen | Disease | Clinical trials | Antibodies | Arthritis | CD40L protein | Blood platelets | Lymphocytes | Rodents | Thromboembolism | Antinuclear antibodies | Deoxyribonucleic acid--DNA | Immune system | Lupus | Antigens | Polyethylene | Immunoglobulins | Immunomodulation | Fab | Rheumatology | Antiphospholipid antibodies | Gene expression | Ribonucleic acid--RNA | Studies | Lymphocytes B | Antigen-presenting cells | Ligands | Autoimmune diseases | Index Medicus
Journal Article